PMID- 23862076
OWN - NLM
STAT- MEDLINE
DCOM- 20131230
LR  - 20211021
IS  - 1687-5443 (Electronic)
IS  - 2090-5904 (Print)
IS  - 1687-5443 (Linking)
VI  - 2013
DP  - 2013
TI  - Neural plasticity and proliferation in the generation of antidepressant effects: 
      hippocampal implication.
PG  - 537265
LID - 10.1155/2013/537265 [doi]
LID - 537265
AB  - It is widely accepted that changes underlying depression and antidepressant-like 
      effects involve not only alterations in the levels of neurotransmitters as 
      monoamines and their receptors in the brain, but also structural and functional 
      changes far beyond. During the last two decades, emerging theories are providing 
      new explanations about the neurobiology of depression and the mechanism of action 
      of antidepressant strategies based on cellular changes at the CNS level. The 
      neurotrophic/plasticity hypothesis of depression, proposed more than a decade 
      ago, is now supported by multiple basic and clinical studies focused on the role 
      of intracellular-signalling cascades that govern neural proliferation and 
      plasticity. Herein, we review the state-of-the-art of the changes in these 
      signalling pathways which appear to underlie both depressive disorders and 
      antidepressant actions. We will especially focus on the hippocampal cellularity 
      and plasticity modulation by serotonin, trophic factors as brain-derived 
      neurotrophic factor (BDNF), and vascular endothelial growth factor (VEGF) through 
      intracellular signalling pathways-cAMP, Wnt/ beta -catenin, and mTOR. Connecting the 
      classic monoaminergic hypothesis with proliferation/neuroplasticity-related 
      evidence is an appealing and comprehensive attempt for improving our knowledge 
      about the neurobiological events leading to depression and associated to 
      antidepressant therapies.
FAU - Pilar-Cuellar, Fuencisla
AU  - Pilar-Cuellar F
AD  - Departamento de Fisiologia y Farmacologia, Instituto de Biomedicina y 
      Biotecnologia de Cantabria, Universidad de Cantabria-CSIC-IDICAN, Santander, 
      Cantabria, Spain.
FAU - Vidal, Rebeca
AU  - Vidal R
FAU - Diaz, Alvaro
AU  - Diaz A
FAU - Castro, Elena
AU  - Castro E
FAU - dos Anjos, Severiano
AU  - dos Anjos S
FAU - Pascual-Brazo, Jesus
AU  - Pascual-Brazo J
FAU - Linge, Raquel
AU  - Linge R
FAU - Vargas, Veronica
AU  - Vargas V
FAU - Blanco, Helena
AU  - Blanco H
FAU - Martinez-Villayandre, Beatriz
AU  - Martinez-Villayandre B
FAU - Pazos, Angel
AU  - Pazos A
FAU - Valdizan, Elsa M
AU  - Valdizan EM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130619
PL  - United States
TA  - Neural Plast
JT  - Neural plasticity
JID - 100883417
RN  - 0 (Antidepressive Agents)
SB  - IM
MH  - Antidepressive Agents/pharmacology/*therapeutic use
MH  - Cell Proliferation/*drug effects
MH  - Depressive Disorder/*drug therapy/physiopathology
MH  - Hippocampus/*drug effects/physiopathology
MH  - Humans
MH  - Neuronal Plasticity/*drug effects/physiology
MH  - Signal Transduction/drug effects/physiology
PMC - PMC3703717
EDAT- 2013/07/19 06:00
MHDA- 2014/01/01 06:00
PMCR- 2013/06/19
CRDT- 2013/07/18 06:00
PHST- 2013/03/04 00:00 [received]
PHST- 2013/05/01 00:00 [revised]
PHST- 2013/05/08 00:00 [accepted]
PHST- 2013/07/18 06:00 [entrez]
PHST- 2013/07/19 06:00 [pubmed]
PHST- 2014/01/01 06:00 [medline]
PHST- 2013/06/19 00:00 [pmc-release]
AID - 10.1155/2013/537265 [doi]
PST - ppublish
SO  - Neural Plast. 2013;2013:537265. doi: 10.1155/2013/537265. Epub 2013 Jun 19.